Article Text
ORIGINAL ARTICLE
What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?
Abstract
Three well-designed and conducted randomized phase 3 trials have revealed that the intraperitoneal administration of cisplatin-based chemotherapy as primary treatment of small-volume residual advanced ovarian cancer improves both progression-free and overall survivals compared to an all intravenous cisplatin-based regimen. Based on very reasonable extrapolations from existing evidence-based data, a number of possible “options” can be proposed that use the intraperitoneal route for delivery of chemotherapy in this clinical setting
- chemotherapy
- cisplatin
- intraperitoneal chemotherapy
- ovarian cancer